Winship's senior leadership together constitutes Its Executive Committee, the major decision-making body of the cancer center. The senior leadership has been assembled over the last decade, with a mission to define Winship's scientific priorities and provide oversight to their implementation. The group is led by Walter J. Curran, Jr., M.D., who was appointed Winship Executive Director in September 2009. Dr. Curran, a highly accomplished cancer physician and researcher, has broad authority over all cancer-related research, clinical and educational activities at Emory University. He led the development of a comprehensive strategic plan for Winship and devotes 50% of his time to Winship leadership and the administration of the Cancer Center Support Grant (CCSG). In October 2009, Dr. Curran appointed Fadlo R. Khuri, M.D., as Deputy Director of Winship, with responsibilities defined to include representing the center director at major university and health care functions and focusing on the scientific success and cross-fertilization of the research programs. Dr. Curran has assembled a highly effective team that includes Diane Cassels, M.S., Executive Administrator; Paul W. Doetsch, Ph.D., Associate Director for Basic Research; Edmund K. Waller, M.D., Ph.D., Associate Director for Clinical Research; Kimberiy Kerstann, Ph.D., Associate Director for Research Administration; Joseph Lipscomb, Ph. D., Associate Director for Population Sciences; and most recently, Deborah W. Bruner, Ph.D., R.N., Associate Director for Outcomes Research. Support is requested for all of the above individuals commensurate with their CCSG responsibilities. In addition, Rein Saral, M.D., an accomplished physician leader, serves as Associate Director for Community Affairs and Outreach, Charles Staley, M.D., a nationally prominent surgical oncologist serves as Associate Director for Clinical Affairs, and Dong M. Shin, M.D., a highly accomplished physician-scientist, is Associate Director for Academic Development. These individuals are supported by institutional funds, and no CCSG funds are requested. This group meets twice monthly and serves as the primary deliberative body that advises the Executive Director on major issues including the allocation of Winship's funds, space, and other resources. The Winship senior leadership has supported the development of a significant number of large multi-investigator grants, including a Head and Neck Cancer SPORE grant, several P01's, a large NASA center grant, and Emory's designation as a member of the NCI Chemical Biology Consortium.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
4P30CA138292-08
Application #
9042950
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2016-04-01
Budget End
2017-03-31
Support Year
8
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Richardson, Alessandra M; Havel, Lauren S; Koyen, Allyson E et al. (2018) Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell-Cancer-Associated Fibroblast Interactions during Collective Invasion. Clin Cancer Res 24:420-432
Goldstein, Jordan S; Nastoupil, Loretta J; Han, Xuesong et al. (2018) Disparities in survival by insurance status in follicular lymphoma. Blood 132:1159-1166
Guidot, Daniel M; Switchenko, Jeffrey M; Nastoupil, Loretta J et al. (2018) Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility. Leuk Lymphoma 59:888-895
Jin, Lingtao; Chun, Jaemoo; Pan, Chaoyun et al. (2018) MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. Cancer Cell 34:315-330.e7
Chowdhary, Mudit; Okwan-Duodu, Derick; Switchenko, Jeffrey M et al. (2018) Angiotensin receptor blockade: a novel approach for symptomatic radiation necrosis after stereotactic radiosurgery. J Neurooncol 136:289-298
Chen, Zhengjia; Zheng, Youyun; Wang, Zhibo et al. (2018) Interactive calculator for operating characteristics of phase I cancer clinical trials using standard 3+3 designs. Contemp Clin Trials Commun 12:145-153
Halani, Sameer H; Yousefi, Safoora; Vega, Jose Velazquez et al. (2018) Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways. NPJ Precis Oncol 2:24
Ferris, Matthew J; Liu, Yuan; Ao, Jingning et al. (2018) The addition of chemotherapy in the definitive management of high risk prostate cancer. Urol Oncol 36:475-487
Halicek, Martin; Little, James V; Wang, Xu et al. (2018) Deformable Registration of Histological Cancer Margins to Gross Hyperspectral Images using Demons. Proc SPIE Int Soc Opt Eng 10581:
Cassidy, Richard J; Switchenko, Jeffrey M; El-Deiry, Mark W et al. (2018) Disparities in Postoperative Therapy for Salivary Gland Adenoid Cystic Carcinomas. Laryngoscope :

Showing the most recent 10 out of 331 publications